Surgery Partners, Inc.
23.225USD
+7.4750 (+47.46%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SGRY.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.5B | 2.7B | 3.1B | 3.3B | 3.2B | 2.8B |
| Q1 | 596.2M | 666.2M | 717.4M | 776.0M | 810.9M | — |
| Q2 | 615.4M | 667.6M | 762.1M | 826.2M | 848.9M | — |
| Q3 | 620.6M | 674.1M | 770.4M | 821.5M | 819.5M | — |
| Q4 | 707.1M* | 735.4M* | 864.4M* | 885.0M* | 676.5M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.590 | -.090 | -1.33 | -.610 | .345 | .170 |
| Q1 | .140 | -.200 | -.100 | -.300 | -.280 | — |
| Q2 | -.210 | .150 | -.120 | -.020 | -.120 | — |
| Q3 | -.280 | -.040 | -.250 | -.180 | .115 | — |
| Q4 | -.254* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.008* |
| -.860* |
| -.118* |
| .150 |
| — |
Debt level and coverage